Designation supports accelerated access for investigational antibody

EC expands use to protect youngest children

New therapy aims to tackle antibiotic resistance

Regulators assess PB016 vedolizumab biosimilar applications

Researchers highlight minimally invasive monitoring potential

First-in-human evaluation of infinitopes’ therapeutic platform

First IBAT inhibitor for PBC cholestatic pruritus

Designation supports pivotal trials for emerging candidates

Phase 3 data show strong benefit for two therapies

First patient enrolled in pivotal coronary study